Martin John Alexander 4
4 · ESSA Pharma Inc. · Filed Oct 15, 2025
Insider Transaction Report
Form 4
ESSA Pharma Inc.EPIX
Martin John Alexander
Director
Transactions
- Disposition to Issuer
Common Shares
2025-10-09−14,299→ 0 total
Footnotes (1)
- [F1]On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.